The phase I results ( n = 10 ) established the safety of cixutumumab 6 mg/kg/week intravenously , erlotinib 100 mg/day orally , and G 1000 mg/m ( 2 ) intravenously on days 1 , 8 , and 15 of a 28-day cycle .